公司資料
Protagonist Therapeutics Inc 股價、新聞與催化劑
- 股票代碼:
- PTGX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
158.62 USD (+2.27%)
收盤價
最後更新: 2026年8月17日
6B USD
市值
股價為何變動
As of Aug 17, 2026, PTGX closed up 2.27% at $158.62. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Protagonist Therapeutics is a biotechnology company focused on peptide-based medicines and inflammatory disease. Its story is built around using peptide chemistry and targeted biology to address immune-mediated disorders.
所在地與產業分類
Protagonist is headquartered in the United States and listed on NASDAQ. It sits in specialty immunology biotechnology.
商業模式特徵
The company depends on clinical validation, partnership strategy, and the ability to create value from a focused pipeline. Investors watch data, launch prospects, and strategic updates.
生技產業定位
Protagonist occupies a premium peptide-immunology niche within biotech. It has meaningful platform depth, but remains sensitive to clinical and partnership milestones.
未來催化劑
- Protagonist's catalysts are icotrokinra and the broader inflammatory-disease pipeline, where clinical and regulatory updates can materially move the stock. The company remains highly data-sensitive.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。